Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miasartan potassium
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Miasartan potassium is a small molecule angiotensin II receptor type 1 (AT1) antagonist developed by Shandong Huasu Pharmaceutical for the treatment of hypertension. As an angiotensin receptor blocker (ARB), it selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby blocking the hormone's vasoconstrictive and aldosterone-secreting effects. This mechanism leads to systemic vasodilation and a reduction in blood pressure. The drug is classified as a Class 1 innovative chemical drug in China and is currently in the preclinical stage of development.
- Other names
- 美阿沙坦钾美阿沙坦钾片
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on miasartan potassium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miasartan potassium.